Lino Rodrigues

1.2k total citations
23 papers, 764 citations indexed

About

Lino Rodrigues is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Lino Rodrigues has authored 23 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 10 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in Lino Rodrigues's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (8 papers). Lino Rodrigues is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (8 papers). Lino Rodrigues collaborates with scholars based in United States, Japan and Brazil. Lino Rodrigues's co-authors include Yiran Hu, Edward Tam, H. W. Reesink, Massimo Colombo, Beat Müllhaupt, Thomas Podsadecki, A Maieron, Yves Horsmans, Pietro Andreoné and Ola Weiland and has published in prestigious journals such as Gastroenterology, Hepatology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Lino Rodrigues

23 papers receiving 743 citations

Peers

Countries citing papers authored by Lino Rodrigues

Since Specialization

Citations

This map shows the geographic impact of Lino Rodrigues's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lino Rodrigues with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lino Rodrigues more than expected).

Fields of papers citing papers by Lino Rodrigues

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lino Rodrigues. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lino Rodrigues. The network helps show where Lino Rodrigues may publish in the future.

Co-authorship network of co-authors of Lino Rodrigues

This figure shows the co-authorship network connecting the top 25 collaborators of Lino Rodrigues. A scholar is included among the top collaborators of Lino Rodrigues based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lino Rodrigues. Lino Rodrigues is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis 2023 ·Journal of Cystic Fibrosis ·Stephanie E. Chiuve, Daniel Fife, G Leitz, (unknown), (unknown), (unknown), Lino Rodrigues, Dennis L. Decktor, Christopher F. Dowd, Bruce C. Marshall, Drucy Borowitz	4
2	Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection 2020 ·Clinical Gastroenterology and Hepatology ·Eli Zuckerman, Julio Gutiérrez, Douglas E. Dylla, Victor de Lédinghen, Andrew J. Muir, Michael Gschwantler, Massimo Puoti, Florin Alexandru Căruntu, Jihad Slim, Frederik Nevens, Samuel H. Sigal, Stanley M. Cohen, Linda Fredrick, (unknown), Lino Rodrigues, John Dillon	15
3	Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil 2020 ·Annals of Hepatology ·(unknown), Hugo Cheinquer, Lino Rodrigues, (unknown), Mário Reis Álvares‐da‐Silva, José Valdez Madruga, Edison Roberto Parise, Mário Guimarães Pessôa, Juvêncio José Duailibe Furtado, Márcia G. Villanova, (unknown), (unknown), (unknown), Giovanni Faria Silva, Linda Fredrick, Preethi Krishnan, Margaret Burroughs, Tânia Reuter	7
4	IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study 2019 ·Robert S. Brown, C. Hézode, Stanley Wang, Marı́a Buti, Wan‐Long Chuang, Humberto Aguilar, Gábor Horváth, (unknown), Federico Rodríguez-Pérez, Eric Cohen, Yiran Hu, Gretja Schnell, Chih‐Wei Lin, Lino Rodrigues, Roger Trinh, Federico Mensa	8
5	PREVALENCE AND GENOTYPE DIVERSITY OF ANAL HPV INFECTION AMONG HIV-INFECTED WOMEN IN BELEM, PARA, NORTH OF BRAZIL 2018 ·International Journal of Microbiology Research ·Lino Rodrigues, Ricardo Ishak, Antônio Carlos Rosário Vallinoto, (unknown), Vânia Nakauth Azevedo, Rodrigo Vellasco Duarte Silvestre, (unknown), (unknown), (unknown), Luiz Fernando Almeida Machado	1
6	294 - Retreatment of Patients who Failed Glecaprevir/Pibrentasvir Treatment for Hepatitis C Virus Infection 2018 ·Gastroenterology ·David Wyles, Ola Weiland, Betty Yao, Robert Reindollar, Frank Weilert, Jean‐François Dufour, Stuart C. Gordon, Fred Poordad, Albrecht Stoehr, Ashley Brown, Stefan Mauss, Suvajit Samanta, Edward Tam, Lino Rodrigues, Roger Trinh	6
7	Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients 2017 ·Advances in Therapy ·Ken Sato, Kazuaki Chayama, Katia Alves, Hidenori Toyoda, Fumitaka Suzuki, Koji Kato, Lino Rodrigues, Xinyan Zhang, Carolyn M. Setze, Edward Tam, Margaret Burroughs, Rebecca Redman, Hiromitsu Kumada	9
8	Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir 2017 ·Journal of Medical Virology ·Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Carolyn M. Setze, Lino Rodrigues, Katia Alves, Margaret Burroughs, Rebecca Redman, Kazuaki Chayama, Hiromitsu Kumada, Christine A. Collins, Edward Tam	11
9	Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment 2016 ·Clinical Pharmacokinetics ·Amit Khatri, Sandeep Dutta, Thomas Marbury, Richard A. Preston, Lino Rodrigues, Haoyu Wang, Walid M. Awni, Rajeev Menon	13
10	Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients 2015 ·Hepatology ·Kazuaki Chayama, Kazuo Notsumata, Masayuki Kurosaki, Ken Sato, Lino Rodrigues, Carolyn M. Setze, Prajakta Badri, Edward Tam, Regis A. Vilchez, Hiromitsu Kumada	69
11	Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis 2015 ·Hepatology ·Hiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues, Fumitaka Suzuki, Kenji Ikeda, Hidenori Toyoda, Ken Sato, Yoshiyasu Karino, Yasushi Matsuzaki, Kiyohide Kioka, Carolyn M. Setze, Edward Tam, Meenal Patwardhan, Regis A. Vilchez, Margaret Burroughs, Rebecca Redman	118
12	Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects 2015 ·Clinical Therapeutics ·Jiuhong Zha, Prajakta Badri, (unknown), (unknown), Katia Alves, Lino Rodrigues, Rebecca Redman, Sandeep Dutta, Rajeev Menon	11
13	Effect of Co-Medications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics: Analysis of Data from Seven Phase II/III Trials 2015 ·Antiviral Therapy ·Akshanth R. Polepally, Prajakta Badri, Apurvasena Parikh, Lino Rodrigues, (unknown), Sven Mensing, Thomas Podsadecki, Walid M. Awni, Sandeep Dutta, Rajeev Menon	4
14	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection 2014 ·Journal of Infection ·Eric Lawitz, G. W. Sullivan, M. Rodríguez‐Torres, Michael Bennett, Fred Poordad, (unknown), Prajakta Badri, Andrew Campbell, Lino Rodrigues, Yiran Hu, Edward Tam, Regis A. Vilchez	37
15	ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection 2014 ·Gastroenterology ·Pietro Andreoné, Massimo Colombo, Jeffrey Enejosa, İftihar Köksal, Péter Ferenci, A Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, H. W. Reesink, Lino Rodrigues, Yiran Hu, Thomas Podsadecki, Barry Bernstein	273
16	929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients 2014 ·Gastroenterology ·Pietro Andreoné, Massimo Colombo, Jeffrey Enejosa, İftihar Köksal, Péter Ferenci, A Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, H. W. Reesink, Lino Rodrigues, Yiran Hu, Thomas Podsadecki	1
17	Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial 2012 ·Arquivos de Gastroenterologia ·Lino Rodrigues, (unknown), (unknown), (unknown)	7
18	Gastroesophageal reflux episodes in asthmatic patients and their temporal relation with sleep architecture 2008 ·Brazilian Journal of Medical and Biological Research ·(unknown), (unknown), (unknown), Lino Rodrigues, S. Garbuio, Sérgio Tufik, Lia Bittencourt	7
19	Household structure and urban services: neglected targets in the control of visceral leishmaniasis 2005 ·Annals of Tropical Medicine and Parasitology ·Carlos Henrique Nery Costa, Guilherme Loureiro Werneck, Lino Rodrigues, (unknown), (unknown), (unknown), (unknown), Régis Gomes, (unknown)	76
20	The burden of Leishmania chagasi infection during an urban outbreak of visceral leishmaniasis in Brazil 2002 ·Acta Tropica ·Guilherme Loureiro Werneck, Lino Rodrigues, (unknown), (unknown), (unknown), (unknown), Régis Gomes, James H. Maguire, Carlos Henrique Nery Costa	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact